- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06651229
En studie av JNJ-90189892 for residiverende eller refraktær akutt myeloide leukemi eller myelodysplastiske neoplasmer
En fase 1, første-i-menneske, doseeskaleringsstudie av JNJ-90189892 for residiverende eller refraktær akutt myeloide leukemi eller myelodysplastiske neoplasmer
The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose[s] [RP2Ds]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk type of myelodysplastic neoplasms (MDS [type of cancer of the blood and bone marrow, which does not respond to treatment or comes back after treatment]). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, tolerability and efficacy in participants with R/R AML or higher-risk types of MDS at the RP2D regimen(s). The purpose of Part 3 and 4 is to assess the effective dose (recommended Phase 2 combination dose [RP2CD]) that can be safely administered, and dosing regimens of JNJ-90189892 in combination with azacitadine (AZA) + venetoclax (VEN) in participants with R/R AML (part 3) and newly diagnosed (ND) AML (part 4).
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Concord, Australia, 2139
- Concord Hospital
-
Melbourne, Australia, 3000
- Peter MacCallum Cancer Centre
-
Nedlands, Australia, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Marseille, Frankrike, 13273
- Institut Paoli-Calmettes
-
Strasbourg, Frankrike, 67200
- CHRU de Strasbourg - Hopital de Hautepierre
-
Toulouse, Frankrike, 31100
- Institut Claudius Regaud
-
-
-
-
-
Madrid, Spania, 28040
- Hosp Univ Fund Jimenez Diaz
-
Pamplona, Spania, 31008
- Clinica Univ. de Navarra
-
Seville, Spania, 41013
- Hospital Universitario Virgen Rocio
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- A. For Parts 1, 2, and 3: Have a diagnosis, per the world health organization (WHO) 2022 criteria, of (a) Parts 1, 2, and 3: Acute myeloid leukemia (AML) or (b) Parts 1 and 2: Moderate high, high, or very high-risk myelodysplastic neoplasms (MDS) per Molecular International Prognostic Scoring System (IPSS-M); B. For Part 4 only: Previously untreated acute myeloid leukemia (AML) per the WHO 2022 criteria
- Body weight that is greater than or equals to (>=) 40 kg
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Have adequate renal function defined as Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Estimated Glomerular Filtration Rate (eGFR) >=40 milligrams per minute (mL/min) computed with the calculator on the national kidney foundation website
- Participants must have laboratory parameters in the required range
Exclusion Criteria:
- Has a medical history of clinically significant pulmonary compromise, particularly the current need for supplemental oxygen use to maintain adequate oxygenation
- Has evidence of uncontrolled systemic viral, bacterial, or fungal infection. Antimicrobial prophylaxis is permitted
- All participants- Has known allergies, hypersensitivity, or intolerance to JNJ-90189892 or its excipients; Parts 3 and 4- Has known allergies, hypersensitivity, or intolerance to venetoclax (VEN), azacitadine (AZA), or their excipients
- Had major surgery or had significant traumatic injury within 14 days of planned first dose of JNJ-90189892
- Had a prior or concurrent second malignancy with natural history or treatment likely to interfere with any study endpoints of safety or the efficacy of the study treatment
- Has known active central nervous system involvement
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: JNJ-90189892: Monotherapy
Participants will receive JNJ-90189892 in Part 1 (Dose escalation) of the study and the dose levels will be escalated sequentially based on the decisions of the study evaluation team (SET) until the recommended phase 2 dose (RP2D) has been identified. Participants in Part 2 (Dose expansion) will receive JNJ-90189892 at the RP2D determined in Part 1. |
JNJ-90189892 will be administered. |
|
Eksperimentell: JNJ-90189892: In Combination with Azacitadine (AZA)+ Venetoclax (VEN)
Participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) in Part 3 will receive JNJ-90189892+ AZA+VEN to determine the recommended Phase 2 combination dose (RP2CD). The starting JNJ-90189892 dose regimen in Part 3 will be at least 1 dose level below the highest dose level cleared in Part 1 as determined by the SET. In Part 4 participants with newly diagnosed (ND) AML will receive JNJ-90189892+ AZA+VEN starting from the JNJ-90189892 dose level determined safe in Part 3 by the SET. |
JNJ-90189892 will be administered. AZA will be administered. VEN will be administered. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with Adverse events (AEs) by Severity
Tidsramme: From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)
|
|
Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs)
Tidsramme: At least 14 days
|
DLT is defined as any toxicity that requires discontinuation of treatment, any Grade 5 toxicity; Non-hematologic toxicity (Grade 3 or 4) and Hematologic toxicity. |
At least 14 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Serum Concentration of JNJ-90189892
Tidsramme: Up to approximately 2.5 years
|
Serum samples will be analyzed to determine concentrations of JNJ-90189892. |
Up to approximately 2.5 years
|
|
Area Under the Curve Over a Dosing Interval (AUC tau) of JNJ-90189892
Tidsramme: Up to approximately 2.5 years
|
AUC tau is the total observed plasma concentration of JNJ-90189892 in the body during the time between doses. AUCtau of JNJ-90189892 will be reported. |
Up to approximately 2.5 years
|
|
Maximum Observed Plasma Concentration (Cmax) of JNJ-90189892
Tidsramme: Up to approximately 2.5 years
|
Cmax is the maximum observed plasma concentration of JNJ-90189892. Cmax of JNJ-90189892 will be reported. |
Up to approximately 2.5 years
|
|
Minimum Observed Plasma Concentration (Cmin) of JNJ-90189892
Tidsramme: Up to approximately 2.5 years
|
Cmin is the minimum observed plasma concentration of JNJ-90189892. Cmin of JNJ-90189892 will be reported. |
Up to approximately 2.5 years
|
|
Number of Participants with Presence of Anti-JNJ-90189892 Antibodies
Tidsramme: Up to approximately 2.5 years
|
Participants with presence of anti-JNJ-90189892 antibodies will be reported. |
Up to approximately 2.5 years
|
|
Complete Response (CR) in Acute Myeloid Leukemia (AML)
Tidsramme: Up to approximately 2.5 years
|
CR is achieved when a participant has a best response of CR (including complete response with partial hematologic recovery [CRh] or complete response with incomplete hematologic recovery [CRi]) according to the European Leukemia Network (ENL) 2022 criteria. |
Up to approximately 2.5 years
|
|
Overall Response (OR) in Myelodysplastic Neoplasms (MDS)
Tidsramme: Up to approximately 2.5 years
|
OR is achieved when a participant with MDS has a CR (any type, that is CRh or complete response with limited count recovery [CRL]), partial response (PR), or hematologic improvement (HI) according to the International Working Group (IWG) 2023 criteria. |
Up to approximately 2.5 years
|
|
Complete Response in MDS
Tidsramme: Up to approximately 2.5 years
|
CR is achieved when a participant has a best response of CR (including CRh/CRL) according to the IWG 2023 criteria. |
Up to approximately 2.5 years
|
|
Duration of Response (DOR)
Tidsramme: Up to approximately 2.5 years
|
DOR is defined for responsders only, as time from date of initial documentation of a response to the first documented evidence of no reponse, disease progression, relapse, initation of a new systemic anti-cancer therapy (besides hematopoietic stem cell transplant [HSCT]), or death, whichever comes first. |
Up to approximately 2.5 years
|
|
Time to Response (TTR)
Tidsramme: Up to approximately 2.5 years
|
TTR is defined for responders, as the time from the first dose of study drug to first qualifying response. |
Up to approximately 2.5 years
|
|
Number of Participants Achieving Transfusion Independence
Tidsramme: Up to approximately 2.5 years
|
Transfusion independence is defined as the absence of red blood cell (RBC) and platelet transfusions for 8 weeks or longer after starting study treatment for participants with AML and 16 weeks or longer for participants with MDS. |
Up to approximately 2.5 years
|
|
Part 4 Only: Overall Survival (OS)
Tidsramme: Up to approximately 2.5 years
|
OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. |
Up to approximately 2.5 years
|
|
Part 4 Only: Event-Free Survival (EFS)
Tidsramme: Up to approximately 2.5 years
|
EFS is defined as the time from the date of first dose of study treatment to the date of first documented evidence of treatment failure, relapse or death due to any cause, whichever occurs first. |
Up to approximately 2.5 years
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 90189892AML1001
- 2024-514341-10-00 (Registeridentifikator: EUCT number)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .